Search

Search Constraints

You searched for: Author/Creator Sandborn, William J.

Search Results

1. A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease. Issue 5 (22nd December 2019)

4. A Non‐Invasive Serological Test to Assess the Efficacy of Biologic and Non‐Biologic Therapies on the Mucosal Health of Patients With Crohn's Disease: 727. (October 2017)

5. A Randomized, Double‐Blind, Placebo‐Controlled Trial of Ozanimod, an Oral S1P Receptor Modulator, in Moderate to Severe Ulcerative Colitis: Results of the Maintenance Period of the TOUCHSTONE Study: 1841. (October 2015)

6. A Treat to Target Approach Decreases the Rate of CD‐Related Adverse Outcomes versus a Clinical Approach in Patients With Moderate to Severely Active Crohn's Disease: Data From CALM2017 ACG Governors Award for Excellence in Clinical Research: 598. (October 2017)

7. Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials. Issue 11 (6th October 2021)

8. An expert consensus to standardise clinical, endoscopic and histologic items and inclusion and outcome criteria for evaluation of pouchitis disease activity in clinical trials. Issue 10 (18th March 2021)

9. An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials. Issue 7 (7th January 2021)

10. Association of Ustekinumab Concentrations Using Anser® UST Mobility Shift Assay and Clinical Response in Crohn's Disease: 711. (October 2017)